-
Most Recent
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
10 Big Pharma Stocks to Buy
Pharmaceutical stocks and drugmakers are theoretically recession-proof businesses. Still, not all pharma companies are created equal. Here are 10 clear winners
Lilly Should Survive Patent Loss on Blockbuster Drug Zyprexa
On Oct. 23, Eli Lilly will wave goodbye to the U.S. patent on the best-selling drug in its 135-year history. Here's why investors shouldn't be worried.
Bristol-Myers Shares Are a Blue-Chip Keeper
The pharmaceutical giant's stock has posted several new highs and offers an attractive dividend yield.
Illumina Shares Take a Tumble
The biotech's stock hits the skids after the company warns revenue will take a hit.
Onyx’s Staying Power Tied to New Cancer Drug Carfilzomib
Onyx needs the financial boost from its multiple myeloma-treating drug to ween it off dependence on an uneasy partnership with Bayer.
Suit Asks J&J CEO to Return Part of 2010 Pay
J&J CEO Bill Weldon’s gains don’t reflect shareholder pain, some stakeholders say.
Study Results Boost Analyst’s Forecast for Novartis Drug
An analyst boosts his forecast for Novartis' Afinitor based on its promise as a treatment for breast cancer.
FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets
Vivus and Orexigen's diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments.
9 Healthy Biotech Buys
Baby boomers are getting older and in need of more and more treatments, thus the race for the next big blockbuster drug. Smaller biotechs are cashing in.
Shortage of Cancer Drugs Jeopardizes Development of New Treatments
Existing products often are used in new drugs' clinical trials, meaning a cramp in supply can result in delays of even years for new treatments.
The Sweet Taste of Swiss Pharma
Drug-maker Roche Holding Ltd. (RHHBY) could win big from the Swiss franc's pegging to the euro.
Regeneron Shares Get a Spark
A decision by the VA has lifted prospects for the company's key drug -- and its stock.
Boston Scientific CEO Takes a Seat on the Bench
The struggling biotech company decides to wait a year for its new CEO.
Give Bristol-Myers the Benefit Over Merck
Bristol-Myers’ robust new drug portfolio could make it an acquisition target -- and an investing target for you -- but neither stock is a bargain.
Fair or Not, Patent Overhaul Bill Looks Like a Win for Big Pharma
'First-inventor-to-file' system is a victory for Big Pharma and its investors, but a crushing blow to small companies.
Glaxo Alters R&D Process to Ensure Survival in Changing Pharma Industry
GSK has created a "dragon" culture in its R&D process. Here's what it is and why analysts like the Glaxo approach.
AstraZeneca Rolls the Dice on Cholesterol Drug and Comes Up Short
Once the patent for Pfizer's popular Lipitor runs out, cheap knockoffs could start eating away at Crestor sales
Tiny Amarin Banking on Fish Oil Drug Success
The stock's upside is potentially huge if this drug takes off.
